Expertise in
8
conditions

Dr. Saima M. Chohan

Rheumatology
Arizona Arthritis And Rheumatology Associates
5681 W Beverly Ln Ste 100, 
Glendale, AZ 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
8
conditions
Arizona Arthritis And Rheumatology Associates
5681 W Beverly Ln Ste 100, 
Glendale, AZ 

Overview

Saima Chohan is a Rheumatologist practicing medicine in Glendale, Arizona.

Dr. Chohan is highly rated in 8 conditions, according to our data. Her clinical expertise encompasses Rheumatoid Arthritis (RA), Postmenopausal Osteoporosis, Osteoporosis, and Psoriatic Arthritis.

She is actively involved in clinical research, co-authoring 5 peer reviewed articles and participating in 8 clinical trials. Dr. Chohan is currently accepting new patients.

Specialties

Rheumatology

Licenses

Internal Medicine in AZ

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
EMI Health
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

HealthPartners
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MercyCare
  • EPO
  • HMO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 23 Less Insurance Carriers -

Locations

Arizona Arthritis and Rheumatology Associates
5681 W Beverly Ln Ste 100, Glendale, AZ 85306
Other Locations
Foot & Ankle Specialists of Arizona PLLC
4550 E Bell Rd Ste 170, Phoenix, AZ 85032

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis
A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Terminated
Publish Date: March 20, 2026
Intervention Type: Drug
Study Drug: HZN-825
Study Phase: Phase 2
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Pilot Study Evaluating Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Pilot Study Evaluating Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study)
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study)
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Drug
Study Drug: Iloprost
Study Phase: Phase 3
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: October 12, 2023
Intervention Type: Drug
Study Drugs: Olokizumab, Methotrexate
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Drug: Olokizumab
Study Phase: Phase 3
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
View 7 Less Clinical Trials

5 Total Publications

Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study.
Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study.
Journal: Annals of the rheumatic diseases
Published: August 31, 2020
Similar Doctors
Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required
Before you request

Arizona Arthritis And Rheumatology Associates

4550 E Bell Rd Ste 170, 
Phoenix, AZ 
 (10.0 miles away)
480-443-8400
Languages Spoken:
English, Arabic, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Nehad Soloman is a Rheumatologist practicing medicine in Phoenix, Arizona. Dr. Soloman is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Rheumatoid Arthritis (RA), Light Chain Deposition Disease (LCDD), IgG4-Related Disease, and Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus Infections. Dr. Soloman is currently accepting new patients.

Expertise in
37
conditions
Dr. Ravi M. Bhalla
Rheumatology
Expertise in
37
conditions
Dr. Ravi M. Bhalla
Rheumatology
Referral may be required
Before you request

Valley Arthritis Care

13613 W Camino Del Sol Ste 4, 
Sun City West, AZ 
 (11.7 miles away)
623-815-2690
Languages Spoken:
English, Hindi, Punjabi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Ravi Bhalla is a Rheumatologist practicing medicine in Sun City West, Arizona. Dr. Bhalla is highly rated in 37 conditions, according to our data. His clinical expertise encompasses Palindromic Rheumatism, Fibromyalgia, Rheumatoid Arthritis (RA), and Osteoporosis. Dr. Bhalla is board certified in American Board Of Internal Medicine. Dr. Bhalla is currently accepting new patients.

Expertise in
35
conditions
Expertise in
35
conditions
Referral required
Before you request

Arthritis Consultants

12665 W Smokey Dr Ste 140, 
Surprise, AZ 
 (9.0 miles away)
623-219-4040
Languages Spoken:
English, Hindi, Tamil
See accepted insurances
Accepting New Patients
Offers Telehealth

Vijayabhanu Mahadevan is a Rheumatologist practicing medicine in Surprise, Arizona. Dr. Mahadevan is highly rated in 35 conditions, according to our data. Her clinical expertise encompasses Rheumatoid Arthritis (RA), Postmenopausal Osteoporosis, Osteoporosis, and Rhizomelic Pseudopolyarthritis. Dr. Mahadevan is board certified in American Board Of Internal Medicine. Dr. Mahadevan is currently accepting new patients.

Frequently Asked Questions about Dr. Saima M. Chohan

How do I make an appointment with Dr. Saima M. Chohan?

You can book an appointment with Dr. Saima M. Chohan by calling their office at 480-443-8400. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Saima M. Chohan a top-rated expert for Rheumatoid Arthritis (RA)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Saima M. Chohan is classified as an Advanced expert for Rheumatoid Arthritis (RA), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Saima M. Chohan specialize in?

While Dr. Saima M. Chohan is a Rheumatology, they have specific expertise in Rheumatoid Arthritis (RA), Postmenopausal Osteoporosis, and Osteoporosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Rheumatology.

Does Dr. Saima M. Chohan participate in research or clinical trials?

Yes. Dr. Saima M. Chohan has published 5 articles and abstracts on conditions like Rheumatoid Arthritis (RA). You can view a list of Dr. Saima M. Chohan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Saima M. Chohan accept my insurance?

Dr. Saima M. Chohan accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 480-443-8400 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chohan's expertise for a condition
ConditionClose
      View All 8 Advanced Conditions
      View All 39 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile